Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) on November 5 and set a ...

A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the ...

Cancer continues to be a formidable challenge globally, with traditional drug discovery methods focusing on cytotoxic agents and targeted therapies altering the landscape of cancer prognosis and ...

Researchers have combined two gene editing methods. This enables them to quickly investigate the significance of many genetic mutations involved in the development and treatment of cancer.

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA to proteins. But only two percent of the human genome actually encodes ...

Nobel Prize winner and UC Berkeley professor Jennifer Doudna presented developments on her gene research at a UC Santa Barbara Arts & Lectures event on Oct. 22.

New study reveals unexpected consequences of CRISPR-Cas9 gene editing Nov 21, 2023 Team develops new process for evaluating impacts of gene edits that alter rather than 'knock out' DNA code ...

NTLA-2002 is an in vivo gene-editing therapy that is based on clustered regularly interspaced short palindromic repeats (CRISPR)–CRISPR-associated protein 9. NTLA-2002 targets the gene encoding ...

Labroots invites you to the 7th Annual Event in the CRISPR Virtual Event Series 2024 taking place on October 23rd, 2024! This event will continue the conversation of the abilities of CRISPR-based ...